Chlamydia trachomatis: Management in Pregnancy by Allaire, Alex et al.
Infectious Diseases in Obstetrics and Gynecology 3:82-88 (1995)
(C) 1995 Wiley-Liss, Inc.
Chlamydia trachomatis: Management in Pregnancy
Alex Allaire, Lawrence Nathan, and Mark G. Martens
Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA
ABSTRACT
Chlamydia trachomatis is a sexually transmitted disease (STD) commonly diagnosed in pregnancy.
C. trachomatis has been linked to several pregnancy complications including premature rupture of
membranes (PROM), preterm labor and birth, low birth weight, intrauterine growth retardation,
and postpartum endometritis. Infants born to mothers through an infected birth canal are at risk for
acquiring C. trachomatis pneumonitis, conjunctivitis, and nasopharyngeal infection. The standard
treatment of C. trachomatis in pregnancy is erythromycin. Recently, amoxicillin and clindamycin
have been added as alternative regimens for those patients intolerant of erythromycin. This paper
reviews the effectiveness and tolerance ofthe alternative regimens compared with erythromycin and
the success of antepartum treatment of chlamydia in preventing the poor pregnancy outcome and
neonatal morbidity associated with C. trachomatis. (C) 1995 Wiley-Liss, Inc.
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Chlamydia trachomatis is the most common report-
able sexually transmitted disease (STD) in the
United States. 1’2 C. trachomatis is a well-known
cause of pelvic inflammatory disease and cervicitis
in women. The prevalence of chlamydia in preg-
nant women ranges from 2 to 30%.
3-s Certain
women are at increased risk: those receiving care at
public health clinics, being of young age (<25
years), being of nonwhite race, being oflow parity,
having multiple sexual partners, having had a new
sexual partner in the preceding 3 months, using
oral contraception, not using barrier contraception,
and having other STDs or a history of other
STDs. 3’s’6 In pregnant women, C. trachomatis in-
fection carries additional risks compared with non-
pregnant women. The risks of C. trachomatis in
pregnancy and the newborn have recently been re-
viewed. Although conflicting data exist, mater-
nal C. trachomatis infection has several potential
antenatal complications including premature rup-
ture of membranes (PROM), preterm labor and
birth, low birth weight, intrauterine growth retar-
dation, and stillbirth3’6-1 as well as postpartum
and postabortal endometritis.
11-14 Following pas-
sage through an infected birth canal, infants have a
significant risk of acquiring C. trachomatis pneu-
monitis (3-18%), conjunctivitis (18-50%), and na-
sopharyngeal infection (15--20%). 3’15’16 This arti-
cle reviews the success of the standard treatment
regimens in the prevention of these complications
and the alternative treatment regimens that have
recently been proposed.
ANTIBIOTIC TREATMENT OF
CHLAMYDIA INFECTION
Current Treatment Recommendations
The present recommendations ofthe American Col-
lege of Obstetricians and Gynecologists (ACOG)
5
for screening and treating chlamydia in pregnancy
include testing women at their first prenatal visit
who are at high risk based on history and physical
examination (being <25 years of age, having a
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history or presence of other STDs, having had a
new sexual partner within the preceding 3 months,
and having multiple sexual partners), treating again
in the third trimester for those thought to be at high
risk, and treating those that test positive. The Cen-
ters for Disease Control (CDC)
17 recommends sim-
ilar screening (women <25 years of age and those
with new or multiple sexual partners). Routine
screening is not recommended. Tetracycline and
doxycycline are the recommended agents in non-
pregnant women, but these agents are contraindi-
cated in pregnancy because of possible adverse ef-
fects on the fetus, including discoloration of
deciduous teeth. The most widely accepted anti-
chlamydial regimen in pregnancy is erythromycin
base, 500 mg q.i.d, for 7 days, or, if this regimen
is not tolerated, 250 mg q.i.d, for 14 days. 1’5
Erythromycin is commonly thought to have a
high rate of intolerance manifested by gastrointesti-
nal (GI) upset, although this side effect has not
been universally demonstrated. Alternative regi-
mens have recently been recommended by the
ACOG and CDC for those women unable to toler-
ate erythromycin. The ACOG recommends clin-
damycin (300 mg orally t.i.d, for 7 days) and
amoxicillin (500 mg orally t.i.d, for 7 days),
whereas the CDC recommends only amoxicillin as
an alternative.
Alternative Treatment Regimens
Clindamycin
Based on studies reporting success using clindamy-
cin to treat chlamydia in nonpregnant patients, Al-
ger and Lovchik
18 randomly assigned 126 preg-
nant women between 16 and 24 weeks gestation
who had chlamydia cervicitis to receive erythromy-
cin, clindamycin, or placebo. There was no signif-
icant difference in the cure rates for those patients
treated with clindamycin (92.7%) or erythromycin
(83.8%). Erythromycin was associated with signif-
icantly more GI complaints than placebo (23.1%
vs. 2.4%), whereas clindamycin was not. The pa-
tients who experienced side effects were less likely
to be compliant and therefore less likely to be cured.
Amoxicillin
Although ]3-1actam antibiotics were not thought to
be effective against chlamydia infections, in
vitro
8-2 and nonhuman22 studies suggested that
amoxicillin might be efficacious in the treatment of
chlamydia infections in humans. In a small, ran-
domized, double-blind trial comparing amoxicil-
lin, 500 mg b.i.d., with placebo, Bell et al.
23
reported postpartum chlamydial infection in the
infant or mother in 4 of 9 of the amoxicillin group
and 4 of 6 in the placebo group. This study sug-
gested that amoxicillin was ineffective in the treat-
ment of C. trachomatis in pregnant women. Con-
versely, several studies since have shown that
amoxicillin may be an effective treatment. Alex-
ander et al.
z4 reported that amoxicillin at a dose of
500 mg t.i.d, has failure rates equivalent to eryth-
romycin. In a prospective, nonrandomized trial,
Cromblehome et al.
25 compared the efficacy and
patient compliance of treatment with amoxicillin
vs. erythromycin. A total of 193 patients with pos-
itive cervical cultures were asked to participate in
the amoxicillin study. Those who agreed (93) re-
ceived amoxicillin (500 mg orally t.i.d, for 7 days)
and those who refused received erythromycin in the
standard regimen. Tests of cure following treat-
ment revealed no significant difference in the per-
centage cured in the 2 treatment groups
(P > 0.05). In the amoxicillin group, 98.4% had
negative cervical cultures after treatment, compared
with 94.8% treated with erythromycin. There was
also no significant difference in the rate of vertical
transmission as determined by infant culture or
antichlamydial IgG titers. Although there was no
significant difference in the frequency of side ef-
fects, the frequency of stopping the medication be-
cause of intolerance of the drug was significantly
higher with erythromycin (13% vs. 2%). As this
study was neither blinded nor randomized, it may
be biased in that the control patients were those who
refused entry.
Silverman et al.
26 randomized 74 women who
tested positive for chlamydia cervicitis before 36
weeks gestation to receive standard doses of eryth-
romycin or amoxicillin. Test-of-cure cultures were
obtained in 3-4 weeks. The cure rate for amoxicil-
lin was 82.3% and for erythromycin was 84.6%.
This difference was not significant (P 0.91).
Although more patients taking erythromycin expe-
rienced side effects (31.6%), all of which were GI
disturbances, than those taking amoxicillin
(12.8%), this difference was not significant. How-
ever, significantly more patients in the erythromy-
cin group than the amoxicillin group stopped the
therapy as a result of side effects (18.4% vs 0%).
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGYCHLAMYDIA TRACHOMATIS IN PREGNANCY ALLAIRE ET AL.
TABLE I. Clinical trials of clindamycin and amoxicillin in the treatment of C. trachomatis in pregnancy
Study Study Control Treatment Drug
Author type drug drugs results intolerance
Alary et al.
28 Randomized Amoxicillin Erythromycin Amoxicillin--failure 2% Severe GI side effectB31%
Double-blinded Erythromycin--failure 12% Severe GI side effect--6%
Alger and Lovchik
8 Randomized Clindamycin Erythromycin Clindamycin--92% cure rate 10%
Double-blinded Placebo Erythromycin---83.8% cure rate 23%
Placebo-controlled Placebo---22.7% cure rate 2.4%
Bell et al.23 Randomized Amoxicillin Placebo AmoxicillinB5/9 successfully No adverse effects causing
Double-blinded treated discomfort
Placebos2/6 successfully treated
Amoxicillin Erythromycin Amoxicillin---98.4% cure rate
Erythromycin94.8% cure rate
Amoxicillin Erythromycin Amoxicillin4.6% cure rate
Erythromycin--72.3% cure rate
Cromblehome et al.zs Nonrandomized
Unblinded
Magat et al.z7 Randomized
Double-blinded
2% intolerant
13% intolerant
7.7% intolerant
23. I% intolerant
Magat et al.27conducted a larger double-blind,
randomized study comparing amoxicillin and eryth-
romycin for the treatmento C. trachomatis in preg-
nancy. One hundred forty-three women before 36
weeks gestation who had positive cervical cultures
were randomized to receive erythromycin base (500
mg orally q.i.d.) or amoxicillin (500 mg orally
t.i.d.). Of the women receiving full courses of
amoxicillin, 86% were cured as determined by sub-
sequent negative cultures. Of those receiving full
courses of erythromycin, 94% were cured. This
difference was not significant (P 0.14). Almost
half (46.1%) of the patients taking erythromycin
complained of nausea and vomiting, and half of
these patients (23.1%) discontinued treatment be-
cause of the side effects. In the amoxicillin group,
only 5 patients (7.7%) experienced side effects,
with of these patients (1.5%) discontinuing treat-
ment. If successful treatment is defined as complet-
ing the course of medicine and having a negative
test of cure, 84.6% of the amoxicillin-treated group
and 72.3% of the erythromycin-treated group were
successfully treated. The initial power ([3 0.2)
analysis called for 79 patients in each arm; how-
ever, upon completion of the study, unexpected
results suggested that larger studies would be re-
quired to confirm the efficacy of amoxicillin. More
recently, Mary et al.
28 found a treatment failure
rate of 12% in erythromycin-treated patients vs.
2% in amoxicillin-treated patients in a cohort of
199 patients.
Knowing the relative cost of each medication is
useful in prescribing a treatment regimen. The
average wholesale cost to the pharmacist of a 7-day
course of amoxicillin is $3.36.
29 The equivalent
regimen of erythromycin costs $11.76; clindamy-
cin, the most expensive, costs $46.62 for a 7-day
29
COUFS.
Based on the above studies (Table 1) comparing
erythromycin with amoxicillin and clindamycin,
the ACOGs has added amoxicillin and clindamycin
as alternative regimens for the treatment ofchlamy-
dia in pregnancy for those women who are intoler-
ant of erythromycin therapy. However, the CDC
recommends only amoxicillin as an alternate ther-
apy for those patients intolerant of erythromycin.
Based on this discrepancy in recommendations, we
recommend using amoxicillin for women who are
intolerant of erythromycin and clindamycin for pa-
tients intolerant of erythromycin and allergic to
-lactam antibiotics.
Azithromycin
Azithromycin is an azalide antibiotic that, although
chemically related to erythromycin, has unique
pharmacokinetics. It has excellent in vitro and in
vivo activity against C. trachomatis. 3’31 The drug
is rapidly absorbed by the GI tract and widely
distributed to body tissues. It is avidly taken up by
cells, resulting in tissue levels that are up to 100
times greater than serum levels. This effect may be
especially beneficial in the treatment of chlmaydia,
an obligate intracellular pathogen. In addition, mi-
gratory leukocytes, which heavily concentrate
azithromycin, selectively deliver the drug to sites
of inflammation, further increasing the local con-
centration.
3-33
Azithromycin, g orally in a single dose, is a
recommended regimen for chlamydia cervicitis in
nonpregnant women. 1’5 At an average wholesale
84 INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGYCHLAMYDIA TRACHOMATIS IN PREGNANCY ALLAIRE ET AL.
cost of $24.16/g, azithromycin is approximately
twice the cost oferythromycin.
29 The clinical toler-
ance ofazithromycin is superior to erythromycin,
2
and patient compliance may be improved in the
pregnant patient. In addition, patient compliance
may be further enhanced using single-dose therapy
as opposed to multiple-dose regimens for 7-14 days.
Reproductive studies with azithromycin in rats have
revealed no evidence of impaired fertility or ad-
verse fetal outcome.
34 Although azithromycin is
not currently recommended for use in pregnant
women, its similarities to erythromycin have led to
recent studies on its use in the treatment of endocer-
vical chlamydia in pregnancy. Both Bush and
Rosa
3s and Chatterjee and Madar
6 found it to be
equal in efficacy to erythromycin in pregnant pa-
tients.
Although currently the recommended first-line
regimen in the treatment of chlamydia in preg-
nancy, erythromycin therapy is not ideal because of
its high rate of intolerability and its multiple-dose,
1-2 week regimen. Several studies have suggested
that amoxicillin or clindamycin therapy may be
superior to erythromycin. Larger studies are needed
to confirm these results before these agents can be
used as first-line agents. Azithromycin may be an
efficacious and well-tolerated alternative to eryth-
romycin, but its efficacy and safety in pregnancy
are yet to be shown.
EFFECT OF TREATMENT ON
PREGNANCY OUTCOME
The antenatal treatment of chlamydia cervicitis is
beneficial in preventing neonatal infection. Schacter
et al.
7 treated 184 women with cervical chlamydia
infection at 36 weeks gestation with erythromycin.
The women who refused treatment served as con-
trois. Significant GI disturbances occurred in 7%
of those taking erythromycin, and half of these did
not complete the full course of antibiotics. Vertical
transmission was seen in 50% of the infants of
untreated mothers and in only 7% of the infants of
treated mothers. Although this study shows the neo-
natal benefit from treatment, it is flawed by not
being randomized and by using the women who
refused treatment as controls. These authors state
only that the 2 groups were similar in age and
different in racial make-up. It is possible that the 2
groups differed in many more aspects that may be
relevant to the transmission of infection from
mother to infant. Nonetheless, this study provides
some evidence that vertical transmission is prevent-
able.
FitzSimmons et al.
8 followed 33 C. trachomat#
culture-postive women who received treatment at
36 weeks gestation. Of these 33, 18 received a
7-day course of erythromycin. The remainder of
the group failed treatment for a variety of reasons.
Of the group who failed treatment, 3 of the new-
borns were cultured for C. trachomatis and 2 of
these were culture positive. None of the infants of
the women who were adequately treated had posi-
tive cultures for C. trachomatis or had symptomatic
conjunctivitis or pneumonitis. However, this study
was not randomized and is plagued by low numbers
and poor follow-up. Black-Payne et al.
9 had simi-
lar findings using a rapid enzyme immunoassay
antigen detection system (Chlamydiazyme) to screen
asymptomatic women in the third trimester. No
significant differences were noted in the incidence
of respiratory-tract illnesses or conjunctivitis in the
Chlamydiazyme-negative and Chlamydiazyme-pos-
itive treated women. Of those treated with erythro-
mycin, all ofwhom completed the course of antibi-
otics, 16% experienced GI side effects. This study
was not randomized, and the controls were Chlamy-
diazyme-negative women who received no antibiot-
ics. The antibiotics could have had a beneficial
effect on neonatal outcome that was unrelated to
chlamydia infection. In addition, there was no men-
tion of a power analysis, and there exists the possi-
bility of a [3 error.
Although flawed in many respects, the above
studies
37-39 suggest that maternal treatment with
erythromycin prior to delivery can prevent the ver-
tical transmission of C. trachomatis. It is unlikely
that a randomized, double-blinded, placebo-con-
trolled study of the efficacy of prenatal treatment of
chlamydia cervicitis in the prevention of neonatal
infection will be performed. Such a study would be
deemed unethical, given the existing evidence of
neonatal transmission and the ability to prevent
transmission with antimicrobial therapy.
Early studies demonstrated that endocervical
chlamydia infections may result in prematurity and
increased perinatal mortality.
10-16,37-42 Other
studies have not confirmed these findings.4’44
More recent investigations have suggested that these
differences may be a result of recent infection as
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demonstrated by IgM-positive pregnant pa-
tients
44-46 or coinfections such as trichomoniasis.
44
Just as the results of studies of the relationship
between C. trachomatis and pregnancy outcome re-
main controversial, several studies investigating the
effect of antenatal treatment of chlamydia cervicitis
on the incidence of poor outcomes such as PROM,
low birth weight, perinatal mortality, and preterm
labor yield conflicting results. In a retrospective
review of medical records, Cohen et al.
8 compared
244 pregnant women with chlamydia cervicitis who
were successfully treated with 79 patients with
chlamydia cervicitis who were unsuccessfully
treated and 244 chlamydia-free control patients.
The frequency of premature delivery, PROM, pre-
mature contractions, and small-for-gestational-age
infants was significantly lower in the successfully
treated vs. the unsuccessfully treated patients, but
was not significantly different from the control pa-
tients. No significant difference in the frequency of
postpartum endometritis was noted in any of the
groups. The major weakness of this study was the
use of treatment failures as controls. Although the
successfully treated and the unsuccessfully treated
were matched for age, marital status, race, socio-
economic status, gravidity, and parity, there re-
main many other potential confounding variables
in the 2 groups that may be risk factors for the
outcomes studied.
Ryan et al.
6 prospectively followed 2,433
chlamydia-culture-positive and 9,1 culture-neg-
ative pregnant women. Of the C. trachomatis-in-
fected women, 1,1 10 remained untreated through-
out the pregnancy, whereas 1,323 received
treatment until subsequent cultures were negative.
There was a significant increase in the incidence of
PROM and low-birth-weight infants and a de-
crease in neonatal survival in the untreated group
compared with the treated group. No such differ-
ences were noted in the treated group compared
with the culture-negative group. No significant dif-
ference in the incidence of chorioamnionitis was
found in any of the groups. This study provides
evidence that the treatment of C. trachomatis prior
to delivery decreases the incidence of poor preg-
nancy outcome. The strength of this study over the
previous study by Cohen et al. is that the women
who tested positive but were not offered treatment
served as controls, as opposed to using those who
failed treatment as controls. However, its major
weakness is that it was not randomized, and the
determinant of treatment was based on the time
period of enrollment of women for prenatal care.
Although unlikely, as stated by the authors, the
differences in outcome between the 2 C. trachoma-
tis-positive groups could be related to changes in
patient demographics or unrelated institutional
treatment policies during the two periods.
In a double-blind, randomized, placebo-con-
trolled trial, Alger and Lovchik
47 found that the
eradication of C. trachomat# failed to reduce the
incidence of PROM, preterm birth, low birth
weight, or maternal infectious morbidity compared
with controls, although patients with preterm
PROM were more likely to have been infected
with C. trachomatis.
CONCLUSIONS
These studies provide evidence that the treatment
of chlamydia in pregnancy with erythromycin is
efficacious in preventing the poor pregnancy out-
come linked to chlamydia infection and the trans-
mission of chlamydia to the newborn. The major
drawback to erythromycin therapy is its high fre-
quency of GI side effects (23.1-46.1%) and subse-
quent patient discontinuation of therapy because of
the side effects (13-23.1%).
18,25--27 Alternative
regimens, including amoxicillin and clindamycin,
have been recommended by the ACOG and CDC.
These regimens should be reserved as second line
for those who have demonstrated intolerance of
erythromycin, as no study with adequate power has
proved that they are equal or superior in efficacy to
erythromycin.
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